Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP12 | P39900 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
| ▸ | MMP16 | P51512 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27749864 | 0.87 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL25512311 | 0.80 | MMP2 (0.43) | CXCL8PTGS2POLBMMP1MMP2 | |
| SCHEMBL10964084 | 0.79 | PTGS2 (0.39) | SMN1; SMN2LMNACXCL8PTGS2POLB | |
| SCHEMBL3635902 | 0.79 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL27897428 | 0.78 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL23363349 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL998722 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL29814033 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL29757429 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAFAAHPOLBHTT | |
| SCHEMBL2363024 | 0.77 | GABRA1 (0.43) | SMN1; SMN2LMNAFAAHPTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4015504-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3508477-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-10660897-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3508477-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3078658-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10035768-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180179160-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-06-28 | — | — | US | disclosed |
| EP-2585064-B1 | C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20170114017-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-04-27 | — | — | US | disclosed |
| US-20170065604-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. | 2017-03-09 | — | — | US | disclosed |
| US-20130317028-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130172347-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. | 2013-07-04 | — | — | US | disclosed |
| US-8445515-B2 | C5aR antagonists | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| EP-2585064-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011163640-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110275639-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2381778-A1 | C5AR ANTAGONISTS | ChemoCentryx, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| US-20100311753-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010075257-A1 | C5AR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160320-A1 | C5aR ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160320-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-10660897-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20110275639-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20170114017-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20180179160-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-10035768-B2 | C5aR antagonists | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20130317028-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20100311753-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20130172347-A1 | C5AR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2376/4885LMNA 2969/4885CXCL8 1506/4885 |
| US-20170065604-A1 | C5aR ANTAGONISTS | C5AR1, C5AR2, C3AR1 | SMN1; SMN2 2356/4885LMNA 2758/4885CXCL8 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.